Loopbaan van Gary Abromovitz
Eerdere bekende functies van Gary Abromovitz
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| HELEN OF TROY LIMITED | Directeur/Bestuurslid | 01-01-1990 | 24-08-2022 |
| Independent Dir/Board Member | 01-01-1990 | 24-08-2022 | |
Venturis Therapeutics, Inc.
 Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | Directeur/Bestuurslid | 01-02-2005 | 10-08-2012 |
| Independent Dir/Board Member | 01-02-2005 | 10-08-2012 |
Statistieken
Internationaal
| Bermuda | 2 |
| Verenigde Staten | 2 |
Operationeel
| Director/Board Member | 2 |
| Independent Dir/Board Member | 2 |
Sectoraal
| Consumer Durables | 2 |
| Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| HELEN OF TROY LIMITED | Consumer Durables |
| Bedrijven in privébezit | 1 |
|---|---|
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | Commercial Services |
- Beurs
- Insiders
- Gary Abromovitz
- Ervaring